Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: Subgroup analysis of a double-blind randomized controlled trial

Lupus

Volumn 22, Issue 14, 2013, Pages 1470-1478

  Mok, C C ^a   Ying, Shirley K Y ^b   Ma, K M ^a   Wong, C K ^c  

^a TUEN MUN HOSPITAL   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

activity; biomarkers; flares; Lupus; selective estrogen modulation

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CALCITRIOL; CALCIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HOMOCYSTEINE; HYDROXYCHLOROQUINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RALOXIFENE; TACROLIMUS; THROMBOMODULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BONE DENSITY; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEPRESSION; DISEASE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DUODENUM ULCER; DYSPEPSIA; FEMALE; FEMUR NECK; FOLLOW UP; HEARTBURN; HUMAN; INFECTION; LEG CRAMP; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; VERTIGO;

ACTIVITY; BIOMARKERS; FLARES; LUPUS; SELECTIVE ESTROGEN MODULATION;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HOMOCYSTEINE; HUMANS; LUMBAR VERTEBRAE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; POSTMENOPAUSE; PREDNISOLONE; RALOXIFENE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84887973977     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313507987     Document Type: Article

References (32)

1. Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum. 1999 ; 42: 1274-1280
2. Mok CC, Lau CS, Ho CT, et al. Do flares of systemic lupus erythematosus decline after menopause?. Scand J Rheumatol. 1999 ; 28: 357-362
3. Sanchez-Guerrero J, Karlson EW, Liang MH, et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 804-808
4. Costenbader KH, Feskanich D, Stampfer MJ, et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007 ; 56: 1251-1262
5. Bernier MO, Mikaeloff Y, Hudson M, et al. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum. 2009 ; 61: 476-481
6. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 ; 353: 2550-2558
7. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med. 2005 ; 142: 953-962
8. Sturgess AD, Evans DT, Mackay IR, et al. Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol. 1984 ; 13: 11-14
9. Mok CC, To CH, Mak A, et al. Raloxifene for postmenopausal women with systemic lupus erythematosus: A pilot randomized controlled study. Arthritis Rheum. 2005 ; 52: 3997-4002
10. Abdou NI, Rider V, Greenwell C, et al. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: A double-blind placebo-controlled trial. J Rheumatol. 2008 ; 35: 797-797
11. Mok CC, Ying KY, To CH, et al. Raloxifene for prevention of glucocorticoid-induced bone loss: A 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis. 2011 ; 70: 778-784
12. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol. 1992 ; 19: 53-59
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
15. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003 ; 56: 481-490
16. Lahita RG. Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am. 2000 ; 26: 951-968
17. Sthoeger ZM, Zinger H, Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis. 2003 ; 62: 341-346
18. Wu WM, Lin BF, Su YC, et al. Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand J Immunol. 2000 ; 52: 393-400
19. Wu WM, Suen JL, Lin BF, et al. Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice. Immunology. 2000 ; 100: 110-118
20. Apelgren LD, Bailey DL, Fouts RL, et al. The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice. Cell Immunol. 1996 ; 173: 55-63
21. Dayan M, Zinger H, Kalush F, et al. The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations. Immunology. 1997 ; 90: 101-108
22. Sthoeger ZM, Bentwich Z, Zinger H, et al. The beneficial effect of the estrogen antagonist, tamoxifen, on experimental systemic lupus erythematosus. J Rheumatol. 1994 ; 21: 2231-2238
23. Zhang Y, Saha S, Rosenfeld G, et al. Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice. J Rheumatol. 2010 ; 37: 1646-1657
24. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999 ; 282: 637-645
25. Delmas PD, Ensrud KE, Adachi JD, et al. Mulitple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002 ; 87: 3609-3617
26. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: Results of subgroup analyses by age and other factors. Circulation. 2009 ; 119: 922-930
27. Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke. 2009 ; 40: 147-155
28. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med. 2000 ; 160: 3444-3450
29. Barrett-Connor E, Ensrud KE, Harper K, et al. Post-hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther. 2003 ; 25: 919-930
30. Mok CC. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand J Rheumatol. 2006 ; 35: 85-95
31. Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost. 2008 ; 99: 338-342
32. Kung AW, Chao HT, Huang KE, et al. Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women. J Clin Endocrinol Metab. 2003 ; 88: 3130-3136